Leili Rejali

Dr. Leili Rejali

Shahid Beheshti University of Medical Sciences, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LRLeili Rejali
Leili Rejali
RARomina Seifollahi Asl
Romina Seifollahi Asl
FSFatemeh Sanjabi
Fatemeh Sanjabi
NFNayeralsadat Fatemi
Nayeralsadat Fatemi
HAHamid Asadzadeh Aghdaei
Hamid Asadzadeh Aghdaei
Stefania NobiliStefania Nobili
Stefania Nobili
Colorectal cancer (CRC) is the second cause of cancer-related deaths in both sexes globally and presents different clinical outcomes that are described by a range of genomic and epigenomic alterations. Despite the advancements in CRC screening plans and treatment strategies, the prognosis of CRC is dismal. In the last two decades, molecular biomarkers predictive of prognosis have been identified in CRC, although biomarkers predictive of treatment response are only available for specific biological drugs used in stage IV CRC. Translational clinical trials mainly based on “omic” strategies allowed a better understanding of the biological heterogeneity of CRCs. These studies were able to classify CRCs into subtypes mainly related to prognosis, recurrence risk, and, to some extent, also to treatment response. Accordingly, the comprehensive molecular characterizations of CRCs, including The Cancer Genome Atlas (TCGA) and consensus molecular subtype (CMS) classifications, were presented to improve the comprehension of the genomic and epigenomic landscapes of CRCs for a better patient management. The CMS classification obtained by the CRC subtyping consortium categorizes CRC into four consensus molecular subtypes (CMS1–4) characterized by different prognoses. In this review, we discussed the CMS classification in different settings with a focus on its relationships with precursor lesions, tumor immunophenotype, and gut microbiota, as well as on its role in predicting prognosis and/or response to pharmacological treatments, as a crucial step towards precision medicine.

27 May 2015 in Iranian Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
LRLeili Rejali
Leili Rejali
BPBehzad Poopak
Behzad Poopak
MHMandana Hasanzad
Mandana Hasanzad
FSFatemeh Sheikhsofla
Fatemeh Sheikhsofla
AVAmeneh Saadat Varnoosfaderani
Ameneh Saadat Varnoosfaderani
SRSaghar Rabieipoor
Saghar Rabieipoor
Background: Chronic myelogenous leukemia (CML) is a kind of hematopoietic stem-cell cancer. A significant number of CML patients who do not achieve an acceptable response to therapy, show acquired resistance against Imatinib. One of the most considerable causes of resistance against Imatinib as the first line of therapy, are BCR-ABL kinase domain mutations. Objectives: One of the most considerable causes of resistance against Imatinib as the first line of therapy, are BCR-ABL kinase domain mutations. Patients and Methods: The study was performed on 39 CML patients with Imatinib resistance. Basic hematologic parameters in blood samples were checked to identify hematologic response. To identify molecular response, BCR-ABL/ABL ratio was assessed by Real-time PCR. The ABL kinase domain amplification was performed by PCR. Restriction fragment length polymorphism (RFLP) was performed to detect four common mutations (T315I, Y253H, E255K and M351T). Finally the results were approved by direct sequencing. Results: In this study, the Y253H mutation, detected by RFLP method and confirmed by direct sequencing, was the prevalent ABL kinase domain mutation in these 39 CML patients. The G250E, V379I and L384M mutations were found in three different cases with failure molecular response. CML patients with these four ABL kinase domain mutations cannot achieve major molecular response (MMR). In addition, complete hematologic response (CHR) was observed only in the V379I mutated case and not in other mutated patients. Conclusions: Identification of ABL kinase domain mutations may be used as a proper and useful method for improving therapeutic strategies, avoiding delay in treatment and excessive expenditure in CML patients with Imatinib resistance. Keywords: Chronic Myeloid Leukemia; Imatinib Resistance; Genes, abl; Real-Time PCR; RFLP; Sequence Analysis

12 August 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMahsa RezaSoltani
Mahsa RezaSoltani
FFFlora Forouzesh
Flora Forouzesh
ZSZahra Salehi
Zahra Salehi
MZMohammad-Reza Zabihi
Mohammad-Reza Zabihi
LRLeili Rejali
Leili Rejali
ENEhsan Nazemalhosseini-Mojarad
Ehsan Nazemalhosseini-Mojarad
LncPVT1 and CircPVT1 are isoforms for the PVT1 gene and are associated with cancer progression and carcinogenesis. Our study investigated the expression of LncPVT1 and CircPVT1 in colon adenoma polyps. 40 tissues of colorectal polyps and 40 normal-adjacent tissues (NATs) were taken. The expression of LncPVT1 and CircPVT1 was evaluated through qRael-Time PCR. The relation between expression and features of clinicopathological was explored. The ceRNA network was constructed by LncPVT1 and CircPVT1 and predicted miRNAs and miRNAs targets. Further, hub nodes in this network were determined using the cytoHubba package. Over-expressed LncPVT1 and CircPVT1 were differentiated in polyp and NATs. The expression level of LncPVT1 and CircPVT1 were significantly higher in adenoma polyps than in hyperplastic polyps. The area under the curve of the ROC estimate for the LncPVT1 and CircPVT1 was 0.74 and 0.77, respectively. A positive correlation was observed between the LncPVT1 expression and CircPVT1. Three miRNAs, including hsa-miR-484, hsa-miR-24-3p, hsa-miR-423-5p, and CircPVT1, were detected as ceRNA hub nodes. In this study, expression profiles of LncPVT1 and CircPVT1 were significantly higher in precancerous polyps. In addition, based on our in silico analysis, LncPVT1, CircPVT1/miR-484, miR-24-3p, miR-423-5p/PLAGL2 axis might be involved in colon cancer development. LncPVT1 and CircPVT1 can be prescribed as warning problems as potential prognostic biomarkers in patients with pre-CRC colon polyps.

26 March 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
FGFaranak Ghadamyari
Faranak Ghadamyari
MHMohammad Mehdi Heidari
Mohammad Mehdi Heidari
SZSirous Zeinali
Sirous Zeinali
MKMehri Khatami
Mehri Khatami
SMShahin Merat
Shahin Merat
FGFarzaneh Ghasemi
Farzaneh Ghasemi
Background: Familial adenomatous polyposis (FAP) as a colon cancer predisposition syndrome is an autosomal‐dominant inherited condition and is diagnosed by the progress of hundreds or thousands of adenomatous colonic polyps in the colon. This study aims at the nature and effect of Adenomatous Polyposis Coli (APC) gene mutations in FAP tumorigenesis.Methods: The genetic screening of 59 FAP Iranian patients in 10 families was performed by polymerase chain reactions and the direct sequencing of the entire coding exons of the APC gene. To do linkage haplotype analysis and multiplex PCR‐based microsatellite examination, six short tandem repeat loci were selected in this gene. To evaluate and predict the potentially deleterious effects, comprehensive bioinformatics pathogenicity assays were used.Results: A total of 12 germline heterozygous and homozygous nucleotide variations were identified. They included two missense mutations, four nonsense mutations, which would lead to the truncated and nonfunctional protein products, four synonymous or silent variations, and two nucleotide deletions of 1 to 5 bp or frameshift mutations. In addition, three novel heterozygous nonsense mutations were found in exons 10, 14, and 15 of the gene. There was also p.Arg653Met as a novel heterozygote mutation in exon 14 of the gene.Conclusions: Bioinformatics analysis and three‐dimensional structural modeling predicted that these missense and nonsense mutations generally are associated with the deleted or truncated domains of APC and have functional importance and mainly affected the APC protein. These findings may provide evidence for the progress of potential biomarkers and help to understand the role of the APC gene in FAP.

11 July 2014 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
SZSirous Zeinali
Sirous Zeinali
EDElham Davoudi-Dehaghani
Elham Davoudi-Dehaghani
SASarah Azadmehr
Sarah Azadmehr
SDSamira DabbaghBagheri
Samira DabbaghBagheri
HBHamideh Bagherian
Hamideh Bagherian
SSSepideh Sahebi
Sepideh Sahebi

14 April 2022 in Genes
Verified
Journal Article
Open access
PDF file
SHShaghayegh Hosseini
Shaghayegh Hosseini
LRLeili Rejali
Leili Rejali
Zahra (Negin) PezeshkianZahra (Negin) Pezeshkian
Zahra (Negin) Pezeshkian
MMMahtash Malekian
Mahtash Malekian
NFNayeralsadat Fatemi
Nayeralsadat Fatemi
GSGhazal Sherkat
Ghazal Sherkat
TGF-β signaling pathways promote tumour development and control several downstream genes such as CTGF and MMPs. This study aimed to investigate the association between CTGF and MMP-1 mRNA expressions with clinicopathological status and survival rate in colorectal cancer patients. We investigated expression levels of CTGF and MMP-1 genes in paraffin-embedded tumours and adjacent normal tissue blocks (ADJ) by Real Time-PCR. Then, the expression of Smad2 and Smad4 proteins in the TGF-β canonical pathway was evaluated by immunohistochemistry. Finally, the correlation between CTGF, MMP-1, and the canonical TGF-β-signalling pathway with the clinicopathological features was investigated. Expression levels of MMP-1and CTGF were higher in tumours compared with adjacent normal tissues. Overexpression levels of MMP-1 and CTGF were associated with lymph node metastasis, distant metastasis, tumour histopathological grading, advanced stage, and poor survival (p < 0.05). Additionally, a significant association between the upregulation of MMP-1 and tumour location was noted. Upregulation of Smad2 and Smad4 proteins were also significantly correlated with lymph node metastasis, distant metastasis, advanced stage, and poor survival (p < 0.0001). This study showed that canonical TGF-β signalling regulates both CTGF and MMP-1 expression and CRC progression. Moreover, TGF-β signalling and its downstream genes could be used as novel biomarkers and novel approaches for targeted therapy in CRC.